Achilles Therapeutics
PrivateLast Round
Grant
Jul 21, 2022
Est. Valuation
$732.2M
Total Funding Raised
$209.9M
Company Overview
Achilles Therapeutics (NAS: ACHL) is a biopharmaceutical company focused on developing innovative cancer immunotherapies that target clonal neoantigens, with ongoing trials for non-small-cell lung cancer and recurrent or metastatic melanoma.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Drug Discovery, Medical AI
Business Model
B2B2C
Customer Profile
Services & Consulting, Government Contracts, Data as a Service
AI Layer
Infrastructure
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Achilles Therapeutics Comparables
Compare Achilles Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Hangzhou Neoantigen Therapeutics Co., Ltd. | 78% | |
| Arcturus Therapeutics Holdings Inc. | 78% | |
| Turnstone Biologics | 77% |
Achilles Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jul 21, 2022 | ||||
| Grant | May 6, 2021 | ||||
| IPO | Apr 6, 2021 | ||||
| Series C | Nov 17, 2020 | ||||
| Series B | Sep 3, 2019 | ||||
Series A | May 24, 2016 |
Achilles Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Redmile Group | Series B, Series C |
| Forbion Capital Partners | Series B, Series C |
| RA Capital Management | Series C, Series B |
| Boxer Capital | Series C |
| European Commission (Horizon Europe) | Grant |
| Perceptive Advisors | Series B, Series C |
| Syncona | Series B, Series C, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 17, 2020
$70M round led by OrbiMed.
- Sep 3, 2019
$120M round led by RA Capital Management.
Achilles Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Achilles Therapeutics's valuation, stock price, and market status.
Is Achilles Therapeutics a public or private company?
Achilles Therapeutics is a private company.
What is the current stock price of Achilles Therapeutics?
Achilles Therapeutics is a private company, so its shares have no public market price. Caplight tracks Achilles Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Achilles Therapeutics worth (valuation)?
Achilles Therapeutics's valuation is estimated at $732.2M based on funding round data.
Can I buy Achilles Therapeutics stock?
Achilles Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Achilles Therapeutics's last funding round?
Achilles Therapeutics's most recent funding round was Grant on July 21, 2022.
Who are the main investors in Achilles Therapeutics?
Key investors in Achilles Therapeutics include RA Capital Management, Syncona, BofA Securities, OrbiMed, JPMorgan Chase & Co..
Will Achilles Therapeutics IPO soon?
No public IPO plans have been announced for Achilles Therapeutics.
How can I track Achilles Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Achilles Therapeutics's shares on secondary markets.